Zinwell Corporation (TPE:2485)
Taiwan · Delayed Price · Currency is TWD 11.35
+0.05 (0.44%)
Aug 1, 2025, 1:35 PM CST
Intra-Cellular Therapies Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 2,046 | 2,610 | 5,817 | 6,582 | 6,278 | 7,937 | Upgrade | |
Revenue Growth (YoY) | -61.37% | -55.12% | -11.63% | 4.85% | -20.91% | 2.03% | Upgrade |
Cost of Revenue | 2,409 | 2,907 | 5,236 | 6,085 | 6,175 | 7,666 | Upgrade |
Gross Profit | -362.15 | -296.96 | 580.62 | 497.01 | 102.98 | 271.43 | Upgrade |
Selling, General & Admin | 293.47 | 310.08 | 322.87 | 438.14 | 367.45 | 333.65 | Upgrade |
Research & Development | 232.92 | 251.47 | 387.41 | 325.18 | 233.58 | 217.65 | Upgrade |
Operating Expenses | 616.65 | 577.68 | 729.77 | 751.38 | 595.51 | 530.27 | Upgrade |
Operating Income | -978.8 | -874.64 | -149.14 | -254.37 | -492.53 | -258.84 | Upgrade |
Interest Expense | -1.1 | -16.25 | -9.67 | -0.51 | -0.12 | -0.22 | Upgrade |
Interest & Investment Income | 47.18 | 49.56 | 35.11 | 12.14 | 15.86 | 27 | Upgrade |
Currency Exchange Gain (Loss) | 37.05 | 82.51 | 29.85 | 104.32 | 0.03 | -134.64 | Upgrade |
Other Non Operating Income (Expenses) | 130.64 | 137.7 | 63.7 | 118.27 | 99.92 | 190.77 | Upgrade |
EBT Excluding Unusual Items | -765.03 | -621.11 | -30.16 | -20.15 | -376.83 | -175.94 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | - | - | 3.72 | Upgrade |
Gain (Loss) on Sale of Assets | -5.49 | -5.56 | 1.14 | -0.88 | -0 | 1.29 | Upgrade |
Asset Writedown | -76.48 | -76.48 | -244.59 | - | - | -3.81 | Upgrade |
Legal Settlements | - | - | 4.23 | -1.19 | -4.23 | - | Upgrade |
Other Unusual Items | - | - | - | - | -9.78 | - | Upgrade |
Pretax Income | -847.01 | -703.15 | -269.38 | -22.22 | -390.84 | -174.74 | Upgrade |
Income Tax Expense | -14.86 | 26.8 | 17.94 | 45.14 | -19.87 | -18.57 | Upgrade |
Earnings From Continuing Operations | -832.16 | -729.95 | -287.32 | -67.36 | -370.98 | -156.17 | Upgrade |
Minority Interest in Earnings | 36.48 | 13.43 | 215.19 | 67.74 | 16.77 | 5.01 | Upgrade |
Net Income | -795.68 | -716.51 | -72.13 | 0.38 | -354.21 | -151.16 | Upgrade |
Net Income to Common | -795.68 | -716.51 | -72.13 | 0.38 | -354.21 | -151.16 | Upgrade |
Shares Outstanding (Basic) | 318 | 318 | 318 | 318 | 318 | 318 | Upgrade |
Shares Outstanding (Diluted) | 318 | 318 | 318 | 318 | 318 | 318 | Upgrade |
Shares Change (YoY) | - | - | -0.02% | 0.02% | - | - | Upgrade |
EPS (Basic) | -2.50 | -2.26 | -0.23 | 0.00 | -1.11 | -0.48 | Upgrade |
EPS (Diluted) | -2.51 | -2.26 | -0.23 | 0.00 | -1.11 | -0.48 | Upgrade |
Free Cash Flow | -328.49 | 466.52 | 1,275 | -876.42 | -968.77 | 601.03 | Upgrade |
Free Cash Flow Per Share | -1.03 | 1.47 | 4.01 | -2.76 | -3.05 | 1.89 | Upgrade |
Gross Margin | -17.70% | -11.38% | 9.98% | 7.55% | 1.64% | 3.42% | Upgrade |
Operating Margin | -47.83% | -33.51% | -2.56% | -3.86% | -7.85% | -3.26% | Upgrade |
Profit Margin | -38.88% | -27.45% | -1.24% | 0.01% | -5.64% | -1.90% | Upgrade |
Free Cash Flow Margin | -16.05% | 17.87% | 21.92% | -13.31% | -15.43% | 7.57% | Upgrade |
EBITDA | -759.55 | -650.81 | 193.16 | 20.84 | -255.6 | -17.14 | Upgrade |
EBITDA Margin | -37.12% | -24.93% | 3.32% | 0.32% | -4.07% | -0.22% | Upgrade |
D&A For EBITDA | 219.25 | 223.82 | 342.31 | 275.2 | 236.93 | 241.7 | Upgrade |
EBIT | -978.8 | -874.64 | -149.14 | -254.37 | -492.53 | -258.84 | Upgrade |
EBIT Margin | -47.83% | -33.51% | -2.56% | -3.86% | -7.85% | -3.26% | Upgrade |
Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.